Cannabis Global (CBGL) 10-Q/A 20 Jan 21 2021 Q1 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Nov. 30, 2020	Jan. 12, 2021
Document And Entity Information
Entity Registrant Name	CANNABIS GLOBAL, INC.
Entity Central Index Key	0001413488
Document Type	10-Q/A
Document Period End Date	Nov. 30, 2020
Amendment Flag	true
Amendment description	This Amendment to the Registrant’s Form 10-Q for the quarter ended November 30, 2020, corrects disclosures for conversion prices of a convertible note entered into January 5, 2021, as reported in Note 14 Subsequent Events, page 24.
Current Fiscal Year End Date	--08-31
Document Fiscal Period Focus	Q1
Is Entity a Shell Company?	false
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity File Number	000-27039
Entity Common Stock, Shares Outstanding		42,778,826
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Document Fiscal Year Focus	2021
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	false

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Nov. 30, 2020	Aug. 31, 2020
Current Assets:
Cash	$ 59,885	$ 2,338
Accounts Receivable	810	0
Inventory	75,825	75,338
Total Current Assets	136,520	77,676
Machinery & Equipment- Net	24,506	25,406
Other Assets
Long-Term Investments	2,512,918	1,714,903
Intangible Assets	500,000	500,000
Security Deposit	7,200	7,200
TOTAL ASSETS	3,181,144	2,325,185
Current Liabilities:
Accounts Payable	245,937	234,707
Accounts Payable - Related Party	1,139	1,139
Accrued Interest	95,967	33,301
Convertible Notes, Net of Debt Discount of $678,246 and $0, respectively	2,123,871	1,865,733
Derivative Liability	1,139,952	1,125,803
Note Payable - Related Party	499,788	499,788
Total Current Liabilities	4,106,654	3,760,471
Total Liabilities	4,106,654	3,760,471
Stockholder's Equity (Deficit)
Preferred Stock, par value $0.0001, 10,000,000 shares Authorized, 6,000,000 shares Issued and Outstanding at November 30, 2020 and August 31, 2020	600	600
Common Stock, par value $0.001, 290,000,000 shares Authorized, 39,714,845 at November 30, 2020 and 27,082,419 shares Issued and Outstanding at August 31, 2020	39,712	2,708
Additional Paid-In Capital	5,442,391	4,618,168
Shares to be issued	1,960	187
Accumulated Deficit	(6,410,173)	(6,056,949)
Total Stockholder's Equity (Deficit)	(925,510)	(1,435,286)
TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY (DEFICIT)	$ 3,181,144	$ 2,325,185

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Nov. 30, 2020	Aug. 31, 2020
Statement of Financial Position [Abstract]
Convertible Notes, Debt Discount Current	$ 678,246	$ 0
Preferred stock, par or stated value per share (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	6,000,000	6,000,000
Preferred stock, shares outstanding	6,000,000	6,000,000
Common stock, par or stated value per share (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	290,000,000	290,000,000
Common stock, shares issued	39,714,845	27,082,419
Common stock, shares outstanding	39,714,845	27,082,419

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Nov. 30, 2020	Nov. 30, 2019
Revenues:
Total Revenue	$ 4,530	$ 10,003
Cost of Goods Sold	1,300	2,900
Gross Profit	3,230	7,103
Operating Expenses:
Advertising fees	51,022	1,432
Consulting services	231,301	35,883
Professional fees	50,632	148,955
General and administrative expense	114,436	187,523
Total Operating Expenses	447,391	373,793
Operating Loss	(444,161)	(366,690)
Other Income (Expense)
Interest expense	(772,755)	(31,250)
Changes in Fair Value of Derivative Liabilities	715,677	12,503
Investment Income	148,015	0
Total Other Income (Expense)	90,937	(18,747)
Net Loss	$ (353,224)	$ (385,437)
Basic & Diluted Loss per Common Share	$ (0.02)	$ (0.03)
Weighted Average Common Shares Outstanding	20,335,239	12,752,506
Product Sales [Member]
Revenues:
Total Revenue	$ 4,410	$ 5,003
Consulting Revenue Related Party Member
Revenues:
Total Revenue	0	5,000
Other Income [Member]
Revenues:
Total Revenue	$ 120	$ 0

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)	Class A Preferred Stock	Common Stock	Common Stock to be issued	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Shares at Aug. 31, 2019		12,524,307	1,893,333
Beginning Balance, Value at Aug. 31, 2019		$ 1,253	$ 189	$ 1,187,574	$ (1,127,601)	$ 61,415
Common stock issued for services rendered, Shares		1,893,333	(1,893,333)
Common stock issued for services rendered, Value		$ 189	$ (189)
Shares Issued for Services, Shares		23,333
Shares Issued for Services, value		$ 2		20,881		20,883
Stock based compensation, Share
Stock based compensation, Value				95,670		95,670
Proceeds from common stock subscriptions, Shares		203,333
Proceeds from common stock subscriptions, Value		$ 20		74,980		75,000
Proceeds from common stock subscriptions- to be issued, Shares			260,000
Proceeds from common stock subscriptions- to be issued, Value			$ 26	64,974		65,000
Discount on convertible notes				20,000		20,000
Effects of Reverse stock-split, shares		188,822
Effects of Reverse stock-split, Value		$ 19		(19)
Net Loss					(385,437)	(385,437)
Ending Balance, Shares at Nov. 30, 2019		14,833,128	260,000
Ending Balance, Value at Nov. 30, 2019		$ 1,483	$ 26	1,464,060	(1,513,038)	(47,469)
Beginning Balance, Shares at Aug. 31, 2020	6,000,000	27,082,419	1,871,858
Beginning Balance, Value at Aug. 31, 2020	$ 600	$ 2,708	$ 187	4,618,168	(6,056,949)	(1,435,286)
Stock based compensation, Share		3,400,000
Stock based compensation, Value		$ 3,400		179,600		183,000
Proceeds from common stock subscriptions, Shares		510,204	89,796
Proceeds from common stock subscriptions, Value		$ 510	$ 90	(600)
Common stock to be issued for investment, Shares		7,222,222
Common stock to be issued for investment, Value		$ 7,222		642,778		650,000
Common stock issued in settlement of convertible notes payable and accrued interest, Shares		1,500,000
Common stock issued in settlement of convertible notes payable and accrued interest, Value		$ 1,500		28,500		30,000
Effects of Par value adjustment		24,372	1,683	(26,055)
Net Loss					(353,224)	(353,224)
Ending Balance, Shares at Nov. 30, 2020	6,000,000	39,714,845	1,961,654
Ending Balance, Value at Nov. 30, 2020	$ 600	$ 39,712	$ 1,960	$ 5,442,391	$ (6,410,173)	$ (925,510)

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Nov. 30, 2020	Nov. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (353,224)	$ (385,437)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-Cash Interest Expense	665,464	31,158
Investment income	(148,015)	0
Depreciation Expense	900	698
Stock Based Compensation	183,000	116,553
Changes in Fair Value of Derivative Liabilities	(715,677)	(12,503)
Gain on Debt Cancellation	0	0
Changes In:
Accounts Receivable	(810)	(10,003)
Rent Deposit		0
Inventory	(487)	(15,632)
Accounts Payable	11,230	104,829
Accounts Payable - Related Party	0	0
Accrued Professional and Legal Expenses	0	(5,885)
Accrued R&D Expenses	0	(6,250)
Accrued Interest	62,666	92
Accrued Interest - Related Party	0	0
Net Cash Used in Operating Activities	(294,953)	(182,380)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of Machinery & Equipment	0	0
Net Cash Provided by Investing Activities	0	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Issuance of Common Stock	0	75,000
Proceeds from convertible notes payable	427,500	20,000
Repayment of convertible notes payable	(75,000)	0
Net Cash Provided by Financing Activities	352,500	95,000
Net (Decrease) Increase in Cash	57,547	(87,380)
Cash at Beginning of Period	2,338	152,082
Cash at End of Period	59,885	64,702
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	44,625	0
Franchise Taxes	0	0
Shares issued for investment	2,650,000	0
Shares issued for conversion of notes payable	$ 30,000	$ 0

Organization and Description of

Organization and Description of Business	3 Months Ended
	Nov. 30, 2020
Accounting Policies [Abstract]
Organization and Description of Business	Note 1. Organization and Description of Business We are a research and development company primarily focused on entering a wide array of cannabis, hemp and related market sectors. Our primary objective is to create and commercialize engineered technologies delivering hemp extracts and cannabinoids to the human body. We also invest, or provide managerial services, in specialized areas of the regulated hemp and cannabis industries. Cannabis Global, Inc. is located at 520 S. Grand Avenue, Suite 320, Los Angeles, California 90071. Our telephone number is (310) 986-4929 and our website is www.cannabisglobalinc.com. Our shares of Common Stock are quoted on the OTC Markets Pink Tier, operated by OTC Markets Group, Inc., under the ticker symbol “CBGL.” We incorporated in Nevada in 2005 under the name MultiChannel Technologies Corporation, a wholly owned subsidiary of Octillion Corporation, a development stage technology company focused on the identification, acquisition and development of emerging solar energy and solar related technologies, and related products having the potential for commercialization. In April, 2005, we changed our name to MicroChannel Technologies, Inc., and in June, 2008, began trading on the OTC Markets under the trading symbol “MCTC.” Our business focused on research and development of a patented combination of physical, chemical and biological cues at the “cellular” level to facilitate peripheral nerve regeneration. In August, 2011, we ceased operations and attempted to identify, locate, and if warranted, acquire new commercial opportunities. On June 27, 2018, we changed domiciles from the State of Nevada to the State of Delaware and thereafter reorganized under the Delaware Holding Company Statute (Delaware General Corporation Law Section 251(g). On or about July 12, 2018, we formed two subsidiaries for the purpose of effecting the reorganization. We incorporated MCTC Holdings, Inc. and MCTC Holdings Inc. incorporated MicroChannel Corp. We then effected a merger involving the three constituent entities, and under the terms of the merger we were merged into MicroChannel Corp., with MicroChannel Corp. surviving and our separate corporate existence ceasing. Following the merger, MCTC Holdings, Inc. became the surviving publicly traded issuer and all of our assets and liabilities were merged into MCTC Holdings, Inc.’s wholly owned subsidiary MicroChannel Corp. Our shareholders became the shareholders of MCTC Holdings, Inc. on a one for one basis. On May 25, 2019, Lauderdale Holdings, LLC, a Florida limited liability company, and beneficial owner 70.7% of our issued and outstanding common stock, sold 130,000,000 common shares, to Mr. Robert Hymers, Mr. Edward Manolos and Mr. Dan Nguyen, all of whom were previously unaffiliated parties of the Company. Each individual purchased 43,333,333 common shares for $108,333,333 or an aggregate of $325,000. These series of transactions constituted a change in control. On August 9, 2019, the Company filed a DBA in California registering the operating name Cannabis Global. On July 1, 2019, the Company entered into a 100% business acquisition with Action Nutraceuticals, Inc., a company owned by our CEO, Arman Tabatabaei in exchange for $1,000 (see “Related Party Transactions”). On February 20, 2020, the Company entered into a material definitive agreement with Lelantos Biotech, Inc., a Wyoming corporation (“Lelantos”), and its owners Ma Helen M. Am Is, Inc., a Wyoming corporation (“Helen M.”), East West Pharma Group, Inc., a Wyoming corporation (“East West”), and New Horizons Laboratory Services, Inc., a Wyoming corporation (“New Horizons”). In exchange for intellectual properties owned by Lelantos, the Company agreed to issue 400,000 shares of common stock and convertible promissory notes to Lelantos and its owners. On June 15, 2020, the Company and Lelantos entered into a modification agreement cancelling the Company's obligation to issue 400,000 shares of common stock and the convertible promissory notes. The Company and Lelantos agreed to a purchase price of five hundred thousand dollars ($500,000), payable by the issuance of a promissory note. The aggregate unpaid principal amount of the note is paid in monthly payments of seven thousand, five hundred dollars ($7,500) beginning on September 1, 2020, terminating on February 1, 2025. There is no interest on the note or on the unpaid balance. On March 30, 2020, we completed a redomicile from Delaware to Nevada, and changed the Company’s name to Cannabis Global, Inc. and concurrently its trading symbol to “CBGL.” On May 6, 2020, the Company signed a joint venture agreement with RxLeaf, Inc. (“RxLeaf”) a Delaware corporation, creating a joint venture for the purpose of marketing the Company’s products to consumers. Under the terms of the agreement, the Company will produce products, which will be sold by RX Leaf via its digital marketing assets. The Company agreed to share the profits from the joint venture on a 50/50 basis. On July 22, 2020, we signed a management agreement with Whisper Weed, Inc., a California corporation (“Whisper Weed”). Edward Manolos, a director of the Company, is a shareholder in Whisper Weed (see “Related Party Transactions”). Whisper Weed conducts licensed delivery activity of cannabis products in California. The material definitive agreement requires the parties to create a separate entity, CGI Whisper W, Inc. in California as a wholly owned subsidiary of the Company. The business of CGI Whisper W, Inc. will be to provide management services for the lawful delivery of cannabis in the State of California. The Company will manage CGI Whisper W, Inc. operations. In exchange for the Company providing management services to Whisper Weed through the auspices of CGI Whisper W, Inc., the Company will receive as consideration a quarterly fee of 51% of the net profits earned by Whisper Weed. As separate consideration for the transaction, the Company agreed to issue to Whisper Weed $150,000 in the Company’s restricted common stock, valued for purposes of issuance based on the average closing price of the Company’s common stock for the twenty days preceding the entry into the material definitive agreement. Additionally, the Company agreed to amend its articles of incorporation to designate a new class of preferred shares. The preferred class shall be designated and issued to Whisper Weed in an amount equal to two times the quarterly payment made to the Company. The preferred shares shall be convertible into the Company’s common stock after 6 months, and shall be senior to other debts of the Company. The conversion to common stock will be based on a value of common stock equal to at least two times the actual sales for the previous 90 day period. The Company agreed to include in the designation the obligation to make a single dividend payment to Whisper Weed equal to 90% of the initial quarterly net profits payable by Whisper Weed. As of November 30, 2020, the Company has not issued the common or preferred shares, nor designated the preferred stock series. On August 31, 2020, we entered into a stock purchase agreement with Robert L. Hymers III (“Hymers”). Pursuant to the Stock Purchase Agreement, the Company purchased from Hymers 266,667 shares of common stock of Natural Plant Extract of California Inc., a private California corporation (“NPE”), in exchange for $2,040,000. The purchased shares of common stock represents 18.8% of the outstanding capital stock of NPE on a fully diluted basis. NPE operates a licensed psychoactive cannabis manufacturing and distribution business operation in Lynwood, California. In connection with the stock purchase agreement, the Company became a party to a Shareholders Agreement, dated June 5, 2020, by and among Alan Tsai, Hymers, Betterworld Ventures, LLC, Marijuana Company of America, Inc. and NPE. The Shareholders Agreement contains customary rights and obligations, including restrictions on the transfer of the Shares. Pursuant to the stock purchase agreement, we were required to pay the purchase price in monthly installments of $20,000 for a period of twenty-seven (27) months, with the first payment commencing September 1, 2020 and the remaining payments due and payable on the first day of each subsequent month. At January 1, 2020, we were in arrears for five payments due totally $100,000. Consequently, on January 3, 2021, we entered into a settlement agreement concerning the five delinquent payments by agreeing to issue to Hymers a total of 1,585,791 shares of registered common stock from our S-1 registration statement made effective November 12, 2020 (see Subsequent Events). On September 30, 2020, the Company entered into a securities exchange agreement with Marijuana Company of America, Inc., a Utah corporation (“MCOA”). By virtue of the agreement, the Company issued 7,222,222 shares of its unregistered common stock to MCOA in exchange for 650,000,000 shares of MCOA unregistered common stock. The Company and MCOA also entered into a lock up leak out agreement which prevents either party from sales of the exchanged shares for a period of 12 months. Thereafter the parties may sell not more than the quantity of shares equaling an aggregate maximum sale value of $20,000 per week, or $80,000 per month until all Shares and Exchange Shares are sold. On November 16, 2020, the Company entered into a business acquisition agreement with Ethos Technology LLC, dba Comply Bag, a California limited liability company (“Ethos”). Ethos is a development stage business in the process of entering the market for cannabis trackable storage bags. By virtue of the agreement, Ethos sold, assigned, and transferred to the Company all of Ethos’ business, including all of its assets and associated liabilities, in exchange for the Company’s issuance of an aggregate of 6,000,000 common shares. 3,000,000 shares were due at signing, with 1,500,000 shares being issued to Edward Manolos, and 1,500,000 shares being issued to Thang Nguyen. Mr. Manolos is a director of the Company and a related party. Mr. Nguyen is the brother of Dan Van Nguyen, a director of the Company and a related party. After Ethos ships orders for Ethos products equaling $1,000,000 to unaffiliated parties, the Company will issue to Messrs. Manolos and Nguyen an additional 1,500,000 shares of common stock each.

Going Concern Uncertainties and

Going Concern Uncertainties and Liquidity Requirements	3 Months Ended
	Nov. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern Uncertainties and Liquidity Requirements	NOTE 2 – Going Concern Uncertainties and Liquidity Requirements During quarterly financial reporting period ending November 30, 2020, the Company generated $4,530 in revenues, has an accumulated deficit of $6,410,173, and does not have positive cash flows from operating activities. The Company expects to incur additional losses as begins to execute its business strategy in the cannabinoid marketplace. The Company will be subject to the risks, uncertainties, and difficulties frequently encountered by early-stage companies. The Company may not be able to successfully address any or all of these risks and uncertainties. Failure to adequately do so could cause the Company’s business, results of operations, and financial condition to suffer. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance date of these financial statements. The Company’s ability to continue as a going concern is an issue due to its net losses and negative cash flows from operations, and its need for additional financing to fund future operations. Management plans to obtain necessary funding from outside sources and through the sales of Company shares. There can be no assurance that such funds, if available, can be obtained on terms reasonable to the Company. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty. Based on the Company’s current level of expenditures, management believes that cash on hand is not adequate to fund operations for the next twelve months. Management of the Company is estimating approximately $1,500,000 will be required over the next twelve months to fully execute its business strategy. These can be no assurance the Company will be able to obtain such funds.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Nov. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 – Summary of Significant Accounting Policies Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the amounts reported in those statements. We have made our best estimates of certain amounts contained in our consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. However, application of our accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties, and, as a result, actual results could differ materially from these estimates. Management believes that the estimates, assumptions, and judgments involved in the accounting policies described below have the most significant impact on our consolidated financial statements. We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary. Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Variable Interest Entities The Company accounts for arrangements that are not controlled through voting or similar rights as variable interest entities (“VIEs”). An enterprise is required to consolidate a VIE if it is the primary beneficiary of the VIE. A VIE is created when (i) the equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support from other parties, or (ii) the entity’s equity holders as a group either: (a) lack the power, through voting or similar rights, to direct the activities of the entity that most significantly impact the entity’s economic performance, (b) are not obligated to absorb expected losses of the entity if they occur, or (c) do not have the right to receive expected residual returns of the entity if they occur. If an entity is deemed to be a VIE, the enterprise that is deemed to have a variable interest, or combination of variable interests, that provides the enterprise with a controlling financial interest in the VIE, is considered the primary beneficiary and must consolidate the VIE. Investments where the Company has significant influence, but not control, and joint ventures which are VIEs in which the Company is not the primary beneficiary, are recorded under the equity method of accounting on the accompanying consolidated financial statements. As of November 30, 2020, the Company held a variable interest in an entity for which it directly held an 18.8% equity interest, and indirectly controlled 37.6% of the equity. The entity was not determined to be a VIE under ASC 810, as it did not meet the criteria outlined above. Since the Company indirectly controls less than 50% of the voting interest of the entity, the entity is not consolidated, and the Company accounts for the investment under the equity method of accounting in accordance with ASC 321. Since the entity in which the Company holds its investment does not have a readily determinable fair value, the Company elected to account for the investment under the measurement alternative, accounting for the investment at cost less impairment, plus or minus any changes resulting from observable price changes in orderly transactions for the same investment. See Note 8 for additional information on this investment. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of August 30, 2020 and through the date of this report. The matters assessed included accounts receivable and the carrying value of investments, intangible assets and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods. Cash and Cash Equivalents We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents are held in operating accounts at a major financial institution. Inventory Inventory is primarily comprised of work in progress. Inventory is valued at cost, based on the specific identification method, unless and until the net realizable value for the inventory is lower than cost, in which case an allowance is established to reduce the valuation to the net realizable value. As of August 31, 2020, and August 31, 2019, market values of all of our inventory were at cost, and accordingly, no such valuation allowance was recognized. Deposits Deposits is comprised of advance payments made to third parties, primarily for inventory for which we have not yet taken title. When we take title to inventory for which deposits are made, the related amount is classified as inventory, then recognized as a cost of revenues upon sale (see “Costs of Revenues” below). There were no deposits as of November 30, 2020 or August 31, 2020. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets is primarily comprised of advance payments made to third parties for independent contractors’ services or other general expenses. Prepaid services and general expenses are amortized over the applicable periods which approximate the life of the contract or service period. Accounts Receivable Accounts receivable are recorded at the net value of face amount less any allowance for doubtful accounts. On a periodic basis, we evaluate our accounts receivable and, based on a method of specific identification of any accounts receivable for which we deem the net realizable value to be less than the gross amount of accounts receivable recorded, we establish an allowance for doubtful accounts for those balances. In determining our need for an allowance for doubtful accounts, we consider historical experience, analysis of past due amounts, client creditworthiness and any other relevant available information. However, our actual experience may vary from our estimates. If the financial condition of our clients were to deteriorate, resulting in their inability or unwillingness to pay our fees, we may need to record additional allowances or write-offs in future periods. This risk is mitigated to the extent that we collect retainers from our clients prior to performing significant services. The allowance for doubtful accounts, if any, is recorded as a reduction in revenue to the extent the provision relates to fee adjustments and other discretionary pricing adjustments. To the extent the provision relates to a client's inability to make required payments on accounts receivables, the provision is recorded in operating expenses. As of November 30 2020, and November, 2019, we had $0 and $0 allowance for doubtful accounts, respectively. Property and Equipment, net Property and Equipment is stated at net book value, cost less depreciation. Maintenance and repairs are expensed as incurred. Depreciation of owned equipment is provided using the straight-line method over the estimated useful lives of the assets, ranging from two to seven years. Depreciation of capitalized construction in progress costs, a component of property and equipment, net, begins once the underlying asset is placed into service and is recognized over the estimated useful life. Property and equipment is reviewed for impairment as discussed below under “Accounting for the Impairment of Long-Lived Assets.” We did not capitalize any interest as of November 30, 2020, and as of November 30, 2019. Accounting for the Impairment of Long-Lived Assets We evaluate long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Upon such an occurrence, recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to forecasted undiscounted net cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. For long-lived assets held for sale, assets are written down to fair value, less cost to sell. Fair value is determined based on discounted cash flows, appraised values or management's estimates, depending upon the nature of the assets. We have not recorded any impairment charges related to long-lived assets during the year ended November 30, 2020, and as of November 30, 2019. Beneficial Conversion Feature If the conversion features of conventional convertible debt provides for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature (“BCF”). We record a BCF as a debt discount pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ACF”) Topic 470-20 Debt with Conversion and Other Options. In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and we amortize the discount to interest expense over the life of the debt using the effective interest method. Revenue Recognition In accordance with FASB ASC Topic 606, Revenue Recognition, we recognize revenue when persuasive evidence of a significant financing component exists in our consulting and product sales contracts. We examine and evaluate when our customers become liable to pay for goods and services; how much consideration is paid as compared to the cash selling price of the goods or services; and, the length of time between our performance and the receipt of payment. Product Sales Revenue from product sales, including delivery fees, is recognized at a point in time when control of the promised goods is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods. Generally, we drop-ship orders to our clients with shipping-point or destination terms. For any shipments with destination terms, the Company defers revenue until delivery to the customer. Given the facts that (1) our customers exercise discretion in determining the timing of when they place their product order; and, (2) the price negotiated in our product sales is fixed and determinable at the time the customer places the order, we are not of the opinion that our product sales indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for us or the customer under FASB ASC Topic 606. Costs of Revenues Our policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenues include the costs directly attributable to revenue recognition and includes compensation and fees for services, travel and other expenses for services and costs of products and equipment. Selling, general and administrative expenses are charged to expense as incurred. Stock-Based Compensation Restricted shares are awarded to employees and entitle the grantee to receive shares of restricted common stock at the end of the established vesting period. The fair value of the grant is based on the stock price on the date of grant. We recognize related compensation costs on a straight-line basis over the requisite vesting period of the award, which to date has been one year from the grant date. Income Taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns in accordance with applicable accounting guidance for accounting for income taxes, using currently enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. As of November 30, 2020, and August 31, 2020, we had no liabilities related to federal or state income taxes. Net Income (Loss) Per Common Share We report net income (loss) per common share in accordance with FASB ASC 260, “Earnings per Share”. This statement requires dual presentation of basic and diluted earnings with a reconciliation of the numerator and denominator of the earnings per share computations. Basic net income (loss) per share is computed by dividing net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period and excludes the effects of any potentially dilutive securities. Diluted net income (loss) per share gives effect to any dilutive potential common stock outstanding during the period. The computation does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Nov. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	Note 4 - Net Loss Per Share During fiscal years ending November 30, 2020 and November 30, 2019, the Company recorded a net loss. Basic and diluted net loss per share is the same for those periods.

Notes Receivable

Notes Receivable	3 Months Ended
	Nov. 30, 2020
Notes to Financial Statements
Notes Receivable	Note 5 – Notes Receivable On July 9, 2019, the Company, through its Action Nutraceuticals subsidiary, loaned, Split Tee, LLC (“Split Tee”), a venture associated with Director Edward Manolos, $20,000 to engage in an exploratory research project. An additional $20,000 was supplied to Split Tee on August 23, 2019. The loans carry interest at the rate of 10% per annum and are due in one year for issuance. Because of Mr. Manolos’ association as a director, the Company believes these transactions are defined by 17 CFR § 229.404 - (Item 404) Transactions with related persons, promoters and certain control persons, which would require specific disclosures under the section cited. As of the end of the fiscal year August 31, 2020, the Company determined it is not likely that repayment of the $40,000 note would occur, thus the Company booked an allowance for Bad Debt expense for the amount. As of the end of the November 30, 2020, the balance was zero.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Nov. 30, 2020
Related Party Transactions
Related Party Transactions	Note 6. Related Party Transactions On November 16, 2020, the Company entered into a business acquisition agreement with Ethos Technology LLC, dba Comply Bag, a California limited liability company (“Ethos”). Ethos is a development stage business in the process of entering the market for cannabis trackable storage bags. By virtue of the agreement, Ethos sold, assigned, and transferred to the Company all of Ethos’ business, including all of its assets and associated liabilities, in exchange for the Company’s issuance of an aggregate of 6,000,000 common shares. 3,000,000 shares were due at signing, with 1,500,000 shares being issued to Edward Manolos, and 1,500,000 shares being issued to Thang Nguyen. Mr. Manolos is a director of the Company and a related party. Mr. Nguyen is the brother of Dan Van Nguyen, a director of the Company and a related party. After Ethos ships orders for Ethos products equaling $1,000,000 to unaffiliated parties, the Company will issue to Messrs. Manolos and Nguyen an additional 1,500,000 shares of common stock each. On November 16, 2020, the Company sold an aggregate 3,000,000 shares of Company common stock, par value $0.001, equal in value to $177,000 based on the closing price on November 16, 2020. Of the total sold, 1,500,000 shares of common stock were sold to Edward Manolos and 1,500,000 shares of common stock were sold to Thang Nguyen. The sales were made in regards to the Company’s acquisition of Ethos, and its disclosures under Item 1.01 are incorporated herein by reference. The Company issued the above shares of its common stock pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended, available to the Company by Section 4(a)(2) promulgated thereunder due to the fact that it was an isolated issuance and did not involve a public offering of securities. Messrs. Manolos and Nguyen were “accredited investors” and/or “sophisticated investors” pursuant to Section 501(a)(b) of the Securities Act, who provided the Company with representations, warranties and information concerning their qualifications as “sophisticated investors” and/or “accredited investors.” The Company provided and made available to Messrs. Manolos and Nguyen full information regarding its business and operations. There was no general solicitation in connection with the offer or sale of the restricted securities. Messrs. Manolos and Nguyen acquired the restricted common stock for their own accounts, for investment purposes and not with a view to public resale or distribution thereof within the meaning of the Securities Act. The restricted shares cannot be sold unless subject to an effective registration statement by the Company, or by an exemption from registration requirements of Section 5 of the Securities Act—the existence of any such exemption subject to legal review and approval by the Company.

Note Payable

Note Payable	3 Months Ended
	Nov. 30, 2020
Note Payable
Note Payable	Note 7. Notes Payable On May 25, 2019, the Company issued two notes payable to Company directors Edward Manolos and Dan Nguyen, each in the amount of $16,666,67. The notes, which do not have a defined due date, outline a 5% per annum interest rate. On July 9, 2019, the Company, through its Action Nutraceuticals subsidiary, loaned, Split Tee, LLC (“Split Tee”), a venture associated with Director Edward Manolos, $20,000 to engage in an exploratory research project (see “Related Party Transactions”). An additional $20,000 was supplied to Split Tee on August 23, 2019. The loans carry interest at the rate of 10% per annum and are due in one year for issuance. In addition, The Company, via Action Nutraceuticals subsidiary, invoiced Split Tee $5,000 as a consulting fee. On February 20, 2020, the Company entered into a material definitive agreement with Lelantos Biotech, Inc., a Wyoming corporation (“Lelantos”), and its owners Ma Helen M. Am Is, Inc., a Wyoming corporation (“Helen M.”), East West Pharma Group, Inc., a Wyoming corporation (“East West”), and New Horizons Laboratory Services, Inc., a Wyoming corporation (“New Horizons”). In exchange for intellectual properties owned by Lelantos, the Company agreed to issue 400,000 shares of common stock and convertible promissory notes to Lelantos and its owners. On June 15, 2020, the Company and Lelantos entered into a modification agreement cancelling the Company's obligation to issue 400,000 shares of common stock and the convertible promissory notes. The Company and Lelantos agreed to a purchase price of five hundred thousand dollars ($500,000), payable by the issuance of a promissory note. The aggregate unpaid principal amount of the note is paid in monthly payments of seven thousand, five hundred dollars ($7,500) beginning on September 1, 2020, terminating on February 1, 2025. There is no interest on the note or on the unpaid balance. On February 12, 2020, the Company entered into an Independent Consulting Agreement with a consultant to provide services from February 12, 2020 through December 14, 2020 (the “Consulting Agreement”). Pursuant to the Consulting Agreement, the Company issued to the consultant a Compensation promissory note having a principal amount of $100,000 for the Deferred Compensation portion of the Consulting Agreement. The note matures August 4, 2020 and bears interest at the rate of 8% per annum. In the event, the note is not paid within the Cash Repayment Period (prior to the Maturity Date), the note specifies the holder shall have two options for repayment including: [a] an Alternative Payment Stake Option equal to a 8.5% (or a pro-rated amount if the debt has been partially paid) fully diluted ownership position in the Company after August 4, 2020; or [b] a Buy Out Option, any time after the note has been outstanding for at least one year, equal to the total outstanding shares of the Company on the day of election, times 8.5% times the average closing price of the Company’s common stock over the preceding 30 trading days, times 40% (due and payable within 90 days). Anti-dilution rights are provided for five years on the Compensation note and for 182 days after conversion to an Alternative Payment Stake. The note includes a Leak Out provision, should the Alternative Payment Stake option be elected, whereby no more than 30% of the holdings may be sold during the first 30 days after clearance for trading and no more than 25% of the remaining shares sold during any subsequent 30-day period. The note is secured by a Security Agreement, requires common shares to be reserved, is transferrable and is Senior to other debt of the Company. As of November 30, 2020 and August 31, 2020, the carrying value of the note was $100,000 and accrued interest payable was $6,400 and $4,405, respectively.

Convertible Note Payable

Convertible Note Payable	3 Months Ended
	Nov. 30, 2020
Notes to Financial Statements
Convertible Note Payable	Note 8. Convertible Notes Payable On March 19, 2020, the Company issued a convertible promissory note, payable in tranches, having an aggregate principal amount of $150,000, aggregate original issue discount (OID) of $15,000, and an aggregate of 468,750 three-year warrants exercisable at $0.48/share, which contain certain exercise price reset provisions in the event of dilutive issuances. The notes mature one year from the respective issuance date of each tranche and bear interest at the rate of 10% per annum, payable at maturity. Commencing immediately following the issuances, the noteholder shall have the right to convert all or any part of the outstanding and unpaid principal balance of the note, at any time, into shares of common stock of the Company at a variable conversion price equal to the lower of 60% of the lowest closing trade price of the Company’s common stock, subject to adjustment, during the 25 trading days prior to: (i) the issuance date; or (ii) the conversion date. On March 19, 2020, the first tranche of $50,000, less OID of $5,000, was received, resulting in net proceeds to the Company of $45,000, and the Company issued 156,250 three-year warrants exercisable at $0.48 per share. On May 4, 2020, the second tranche of $25,000, less OID of $2,500, was received, resulting in net proceeds to the Company of $22,500, and the Company issued 78,125 three-year warrants exercisable at $0.48 per share. On July 10, 2020, the third tranche of $25,000, less OID of $2,500 was received, resulting in net proceeds to the Company of $22,500, and the Company issued 78,125 three year warrants exercisable at an initial price of $0.48 per share. As a result of the OID and the variable conversion price, upon issuance, the Company recognized total debt discount of $75,000, which is being amortized to interest expense over the respective term of the tranches. The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the noteholder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. During the three months ended November 30, 2020, the Company repaid principal of $75,000, accrued interest of $3,712 and early repayment interest and penalties of $40,913. As of November 30, 2020 and August 31, 2020, the carrying value of these notes was $14,187 and $37,088, net of debt discount of $10,813 and $62,912 and accrued interest was $979 and $3,431, respectively. In January 2021, the Company paid $39,875 to settle the final tranche, its accrued interest and early repayment penalties in full. On July 21, 2020, the Company issued a convertible promissory note with a principal amount of $78,750, with the Company receiving proceeds of $71,250 after original issue discount of $3,750 and deferred finance costs of $3,750. The note matures on July 21, 2021 and bears interest at 6% per annum. Commencing immediately following the issuances, the noteholder shall have the right to convert all or any part of the outstanding and unpaid principal balance of the note, at any time, into shares of common stock of the Company at a variable conversion price equal to the 60% of the lowest closing trade price of the Company’s common stock, subject to adjustment, during the 30 trading days prior to: the conversion date. As a result of the OID and the variable conversion price, upon issuance, the Company recognized total debt discount of $78,750, which is being amortized to interest expense through the maturity date. The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the noteholder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. As of November 30, 2020, the carrying value of this note was $28,480, net of discount of $50,270, and accrued interest was $1,709. As of August 31, 2020, the carrying value of this note was $8,846, net of debt discount of $69,904 and accrued interest was $531. In August 2020, the Company issued two convertible promissory notes with an aggregate principal amount of $129,250, with the Company receiving proceeds of $117,500 after original issue discount of $11,750. The notes mature in May 2021 and bear interest at 10% per annum. Commencing immediately following the issuances, the noteholder shall have the right to convert all or any part of the outstanding and unpaid principal balance of the note, at any time, into shares of common stock of the Company at a fixed price of $0.1005 per share of common stock. The conversion price may reset to a lower price if the Company issues common stock to any suppliers or vendors. As a result of the OID and the potential result for dilutive issuances, upon issuance, the Company recognized total debt discount of $129,250, which is being amortized to interest expense through the maturity date. The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the noteholder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. As of November 30, 2020 and August 31, 2020, the carrying value of these notes was $51,535 and $8,452, net of debt discount of $77,715 and $120,798 and accrued interest was $3,862 and $632, respectively. The Company also entered into common stock subscription agreements with this lender, totaling share issuances of 3,409,221 (of which 510,204 are to be issued as of August 31, 2020), for cash proceeds of $329,613. In connection with these subscriptions, the Company issued a convertible promissory note of $50,000 for no consideration. The note matures on August 7, 2021 and bears interest at 10$% and is convertible at a fixed price of $0.1631 per share, subject to potential rest in the event the Company issues shares to vendors or suppliers. The Company recognized total debt discount of $50,000, which is being amortized to interest expense over the respective term of the tranches. The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the noteholder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. As of November 30, 2020 and August 31, 2020, the carrying value of these notes was 15,754 and $3,288, net of debt discount of $34,246 and $46,712 and accrued interest was $1,580 and $329, respectively. During the three months ended November 30, 2020, the Company issued three convertible promissory notes to a lender with an aggregate principal amount of $246,000, with the Company receiving proceeds of $237,000 after deferred finance costs of $9,000. The notes matures in August, September and October 2021 and bear interest at 8% per annum. Commencing one hundred eighty (180) days following the issuance date of the note, the noteholder shall have the right to convert all or any part of the outstanding and unpaid principal balance of the note, at any time, into shares of common stock of the Company at variable conversion prices of 63% of the two lowest trading prices during previous fifteen (15) trading day of the Company’s common stock, subject to adjustment. The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the noteholder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. As a result of the variable exercise price and deferred finance costs, the Company recognized total debt discount of $246,000, which is being amortized to interest expense through the maturity date. The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the noteholder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. As of November 30, 2020, the carrying value of these notes was $53,315, net of debt discount of $192,685 and accrued interest was $3,882. On September 2, 2020, the Company issued a convertible promissory note with an aggregate principal amount of $107,000, with the Company receiving proceeds of $100,000 after original issue discount of $5,000 and deferred finance costs of $2,000. The notes mature in September 2021 and bear interest at 12% per annum. Commencing one hundred eighty (180) days following the issuance date of the notes, the noteholders shall have the right to convert all or any part of the outstanding and unpaid principal balance of the note, at any time, into shares of common stock of the Company at variable conversion price of 60% of the lowest previous twenty (20) trading day closing trade prices of the Company’s common stock, subject to adjustment. The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the noteholder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. As a result of the variable exercise price and deferred finance costs, upon issuance, the Company recognized total debt discount of $107,000, which is being amortized to interest expense through the maturity date. As of November 30, 2020, the carrying value of these notes was $26,090, net of debt discount of $80,910 and accrued interest was $3,131. On September 24, 2020, the Company issued a convertible note in the amount of $110,000. The note matures on June 24, 2021 and bears 10% interest rate per annum, with the Company receiving net proceeds of $90,500. The note is convertible into common shares at a fixed conversion price of $0.06 or a conversion discount at rate of 30% to the lowest trading price during the previous twenty (20) trading days to the date of a conversion notice; whichever is lower. The note has monthly principal payments of $24,200 beginning in February 2021. The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the noteholder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note. As of November 30, 2020, the carrying value of these notes was $95,214, net of debt discount of $14,786 and accrued interest was $1,989. Related Parties During the three months ended February 29, 2020, the Company issued two convertible promissory notes having an aggregate principal amount of $133,101 in exchange for accrued expenses owed to related parties, of which $79,333 is payable to the Company’s Chief Executive Officer and $53,768 is payable to the Robert L. Hymers III. The notes mature two years from the respective issuance date and bear interest at the rate of 10% per annum, payable at maturity. The noteholders shall have the right to convert all or any part of the outstanding and unpaid principal balance of the note, at any time, into shares of common stock of the Company at a variable conversion price of 50% of the average of the previous twenty (20) trading day closing prices of the Company’s common stock, subject to adjustment. As a result of the variable conversion prices, upon issuance, the Company recognized total debt discount of $133,101, which is being amortized to interest expense over the term of the notes. On May 22, 2020, the Chief Executive Officer converted $79,333 in principal and $2,608 of accrued interest into 694,902 shares of common stock to be issued having a fair value of $232,792. The conversion resulted in the elimination of $70,313 of remaining debt discount, the elimination of $231,632 of derivative liabilities, and a $10,468 gain on conversion that resulted from a related party and was therefore included in Additional paid-in capital. As of November 30, 2020 and August 31, 2020, the carrying value of the remaining note with the former chief financial officer was $22,670 and $15,884, net of debt discount of $31,098 and $37,884 and accrued interest was $4,479 and $3,138, respectively. In December 2020, the full amount of principal and accrued interest were converted into 878,190 shares of common stock. On April 30, 2020, the Company entered into a settlement agreement with its former Chief Financial Officer (Robert L. Hymers III, (hereinafter referred to as the “CFO”), whereby the CFO resigned and the Company issued a promissory note for $30,000, which represented the remaining amount owed to the CFO for services rendered. The note matures December 31, 2020 and bears interest at the rate of 10% per annum, payable at maturity. The noteholder has the right to convert all or any part of the outstanding and unpaid principal balance of the note, at any time, into shares of common stock of the Company at a fixed conversion price of $0.02 per share, subject to adjustment. As a result of the beneficial conversion price, upon issuance, the Company recognized debt discount of $30,000, which is being amortized to interest expense over the term of the note. In October 2020, the noteholder converted all principal into 1,500,000 shares of common stock. As of November 30, 2020 accrued interest was $1,759. On August 21, 2020 the Company, issued a convertible note pursuant to a Stock Purchase Agreement (the “SPA) to acquire 266,667 shares of common stock of Natural Plant Extract of California Inc., a California corporation (“NPE”), representing 18.8% of the outstanding capital stock of NPE on a fully diluted basis. With the exception of the entry into the subject material definitive agreements, no material relationship exists between the Registrant, or any of the Registrant’s affiliates or control persons and Hymers. Under the terms of the SPA, the Registrant acquired all rights and responsibilities of the equity stake for a purchase price of Two Million Forty Thousand United States Dollars ($2,040,000) (the “Purchase Price”). Relative to the payment of the Purchase Price, the registrant agreed to: 1) pay Hymers Twenty Thousand United States Dollars ($20,000) each month for a period of twenty-seven (27) months, with the first payment commencing September 1, 2020 and the remaining payments due and payable on the first day of each subsequent month until Hymers has received Five Hundred Forty Thousand United Stated Dollars ($540,000), and 2) issue Hymers a convertible promissory note in the amount of One Million Five Hundred Thousand United States Dollars ($1,500,000) (the “Note”). The Note bears interest at ten percent (10%) per annum. The Holder shall have the right at any time six (6) months after the Issuance Date to convert all or any part of the outstanding and unpaid principal, interest, fees, or any other obligation owed pursuant to the note. Conversion Price shall be calculated as follows: 60% of the lowest Trading Price of the common shares during the ten (10) days preceding the date the Company receive a notice of conversion. Unless permitted by the applicable rules and regulations of the principal securities market on which the Common Stock is then listed or traded, in no event shall the Registrant issue upon conversion of or otherwise pursuant to the note and the other notes issued more than the maximum number of shares of Common Stock that the Company can issue pursuant to any rule of the principal United States securities market on which the Common Stock is then traded, which shall be 4.99% of the total shares outstanding at any time. A debt discount of $54,212 on the note payable at issuance was calculated based on the present value of the note using an implied interest rate of 10%. A debt discount of $270,886 was recognized. Accordingly, the Company recorded an initial value of its investment in NPE of $1,714,903. At the time the note becomes convertible, the Company will recognize a derivative liability at fair value related to the embedded conversion option at that time. Prior to these transactions, Robert Hymers III and Alan Tsai each sold equity interest representing a total of 18.8% of the outstanding equity interest of NPE to Edward Manolos, a Director and preferred stockholder of the Company in a private transaction. As a result of these two transactions, the Company beneficially controls approximately 37% of the equity of NPE. After this transaction, a venture capital company controls 40% of the equity interests in NPE, the Company, Alan Tsai and Edward Manolos each control 18.8% and one other entity controls 3.5%. As of the date of this filing, we were in arrears for five payments equaling $100,000, due under the terms of the stock purchase agreement. On January 3, 2021, we entered into a settlement agreement concerning the five delinquent payments by agreeing to issue to Hymers a total of 1,585,791 shares of registered common stock from our S-1 registration statement made effective November 12, 2020 (see Subsequent Events). The Company evaluated its interest in NPE as of November 30, 2020 under ASC 810. Management determined that it had a variable interest in NPE, but that NPE does not meet the definition of a variable interest entity, and does not have an indirect voting interest of greater than 50%. Based on these factors, the investment in NPE by the Company, the investment in NPE will be accounted for as an equity method investment under the measurement alternative available under ASC 321 with the Company recording its share of the profits and losses of NPE at each reporting period. The initial investment balance was $1,714,903 based on the initial fair value estimate of the note payable and convertible note payable issued as consideration for the investment. For the three months ended November 30, 2020, the Company recognized no equity method income or losses due and no impairment of the investment. During the three months ended November 30, 2020, the Company recognized investment income of $148,015 related to the investment in NPE. See Note 9 for further discussion of the accounting treatment of the embedded conversion options of the above promissory notes payable as derivative liabilities

Derivative Liability and Fair V

Derivative Liability and Fair Value Measurements	3 Months Ended
	Nov. 30, 2020
Notes to Financial Statements
Derivative Liability and Fair Value Measurements	Note 9. Derivative Liability and Far Value Measurement Upon the issuance of the convertible promissory notes with variable conversion prices and fixed conversion prices with reset provisions, the Company determined that the features associated with the embedded conversion option embedded in the debentures should be accounted for at fair value, as a derivative liability, as the Company cannot determine if a sufficient number of shares would be available to settle all potential future conversion transactions. At the issuance date of the convertible notes payable during the three months ended November 30, 2020, the Company estimated the fair value of all embedded derivatives of $729,827 using the Black-Scholes Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 373% to 378%, (3) risk-free interest rate of 0.12% to 0.13k %, and (4) expected life of one year. On November 30, 2020, the Company estimated the fair value of the embedded derivatives of $1,139,952 using the Black-Scholes Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 374%, (3) risk-free interest rate of 0.09 to 0.11%, and (4) expected life of 0.3 to 1.1 years. The Company adopted the provisions of ASC 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value. • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets; • Level 2 — Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon Level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. The Company recognizes its derivative liabilities as Level 3 and values its derivatives using the methods discussed below. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed are that of volatility and market price of the underlying common stock of the Company. As of November 30, 2020, the Company did not have any derivative instruments that were designated as hedges. Items recorded or measured at fair value on a recurring basis in the accompanying financial statements consisted of the following items as of November 30, 2020 and August 31, 2020: November 30, Quoted Significant Significant Derivative liability $ 1,139,952 $ — $ — $ 1,139,952 August 31, Quoted Significant Significant Derivative liability $ 1,125,803 $ — $ — $ 1,125,803 The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities for the three months ended November 30, 2020: Balance, August 31, 2020 $ 1,125,803 Transfers in due to issuance of convertible promissory notes 729,826 Transfers out due to repayments of convertible promissory notes (139,431 ) Transfers out due to conversions of convertible promissory notes — Mark to market to November 30, 2020 1,716,198 Balance, November 30, 2020 $ 1,139,952 Gain on change in derivative liability for the three months ended November 30, 2020 $ (576,246 ) Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The simulated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Increases in expected volatility would generally result in higher fair value measurement. A 10% change in pricing inputs and changes in volatilities and correlation factors would not result in a material change in our Level 3 fair value.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Nov. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 - Commitments and Contingencies The Company has entered into a lease for a production and warehouse facility located in Los Angeles, California to produce such products. The term of the lease is 12 months at a base price of $3,600 per month, beginning August 2019. The total financial obligation for the lease as of the end of the reporting period, November 30, 2020, is $0. At this time the lease agreement has ended and the Company rents to same facility on a month to month basis. Our headquarters are located at 520 S. Grand Avenue, Suite 320, Los Angeles, California 90071 where we leased office space under a contract effective August 15, 2019, which expired on August 14, 2020. We now rent the premises on a month-to-month basis and paying $800 per month.

Common Stock

Common Stock	3 Months Ended
	Nov. 30, 2020
Equity [Abstract]
Common Stock	Note 11 - Common Stock The Company affected a reverse split as of September 30, 2019, at the rate of one (1) share for each fifteen (15) shares. All share and per share amounts have been adjusted to reflect the impact of the reverse stock split. As of November 30, 2020, there were 39,714,845 shares of Common Stock issued and outstanding.

Preferred Stock

Preferred Stock	3 Months Ended
	Nov. 30, 2020
Equity [Abstract]
Preferred Stock	Note 12 - Preferred Stock There are 10,000,000 shares of preferred stock, par value $0.0001 per share, of the Company Preferred Stock in one or more series, and expressly authorized the Board of Directors of the Company. On December 16, 2019, the Board of Directors authorized the issuance of 8,000,000 preferred shares as “Series A Preferred Stock.” The Series A Preferred Stock is not convertible into any other form of Securities, including common shares, of the Company. Holders of Series A Preferred Stock shall be entitled to 50 votes for every Share of Series A Preferred Stock beneficially owned as of the record date for any shareholder vote or written consent. On May 28, 2020, Mr. Robert L. Hymers III, a former director and former chief financial officer, returned 2,000,000 Series A Preferred shares to the corporate treasury. As of November 30, 2020, there were 6,000,000 Series A Preferred shares issued and outstanding.

Other Reportable Events

Other Reportable Events	3 Months Ended
	Nov. 30, 2020
Equity [Abstract]
Other Reportable Events	Note 13 - Other Reportable Events On November 16, 2020, the Company entered into a business acquisition agreement with Ethos Technology LLC, dba Comply Bag, a California limited liability company (“Ethos”). Ethos is a development stage business in the process of entering the market for cannabis trackable storage bags. By virtue of the agreement, Ethos sold, assigned, and transferred to the Company all of Ethos’ business, including all of its assets and associated liabilities, in exchange for the Company’s issuance of an aggregate of 6,000,000 common shares. 3,000,000 shares were due at signing, with 1,500,000 shares being issued to Edward Manolos, and 1,500,000 shares being issued to Thang Nguyen. Mr. Manolos is a director of the Company and a related party. Mr. Nguyen is the brother of Dan Van Nguyen, a director of the Company and a related party. After Ethos ships orders for Ethos products equaling $1,000,000 to unaffiliated parties, the Company will issue to Messrs. Manolos and Nguyen an additional 1,500,000 shares of common stock each. On November 16, 2020, the Company sold an aggregate 3,000,000 shares of Company common stock, par value $0.001, equal in value to $177,000 based on the closing price on November 16, 2020. Of the total sold, 1,500,000 shares of common stock were sold to Edward Manolos and 1,500,000 shares of common stock were sold to Thang Nguyen. The sales were made in regards to the Company’s acquisition of Ethos, and its disclosures under Item 1.01 are incorporated herein by reference. The Company issued the above shares of its common stock pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended, available to the Company by Section 4(a)(2) promulgated thereunder due to the fact that it was an isolated issuance and did not involve a public offering of securities. Messrs. Manolos and Nguyen were “accredited investors” and/or “sophisticated investors” pursuant to Section 501(a)(b) of the Securities Act, who provided the Company with representations, warranties and information concerning their qualifications as “sophisticated investors” and/or “accredited investors.” The Company provided and made available to Messrs. Manolos and Nguyen full information regarding its business and operations. There was no general solicitation in connection with the offer or sale of the restricted securities. Messrs. Manolos and Nguyen acquired the restricted common stock for their own accounts, for investment purposes and not with a view to public resale or distribution thereof within the meaning of the Securities Act. The restricted shares cannot be sold unless subject to an effective registration statement by the Company, or by an exemption from registration requirements of Section 5 of the Securities Act—the existence of any such exemption subject to legal review and approval by the Company. On October 30, 2020, the registrant appointed Jim Riley as an independent director. No arrangement or understanding exists between Mr. Riley and any other person with respect to his appointment as independent director. Mr. Riley is not expected to serve on any committee of the Board of Directors. Mr. Riley has no direct or indirect material interest in any current or proposed transaction, since the beginning of the registrant's last fiscal year, in which the registrant was or is to be a participant and the amount involved exceeds $120,000. The registrant and Mr. Riley entered into an independent director agreement concurrent with his appointment. The registrant agreed to compensate Mr. Riley by issuing him an aggregate of 400,000 shares of the registrant’s common stock, vesting in equal amounts over 12 months, with the initial amount vesting on October 30, 2020. In the event Mr. Riley’s directorship terminates beforehand, vested shares shall be determined pro rata to the date of termination. On September 30, 2020, the Company entered into a securities exchange agreement with Marijuana Company of America, Inc., a Utah corporation (“MCOA”). By virtue of the agreement, the Company issued 7,222,222 shares of its unregistered common stock to MCOA in exchange for 650,000,000 shares of MCOA unregistered common stock. The Company and MCOA also entered into a lock up leak out agreement which prevents either party from sales of the exchanged shares for a period of 12 months. Thereafter the parties may sell not more than the quantity of shares equaling an aggregate maximum sale value of $20,000 per week, or $80,000 per month until all Shares and Exchange Shares are sold. On September 24, 2020, the Company issued a convertible note in the amount of $78,000. The note matures on June 24, 2021 and bears 10% interest rate per annum. The note is convertible into common shares at a fixed conversion price of $0.06 or a conversion discount at rate of 30% to the lowest trading price during the previous twenty (20) trading days to the date of a conversion notice; whichever is lower. On September 22, 2020, the Company issued a convertible note in the amount of $78,000. The note matures on September 22, 2021 and bears 8% interest rate per annum. The note is convertible into common shares at 37% discount for the average of the two lowest trading price of the common stock during the 15 trading day period ending on the latest complete trading day prior to the conversion date. On September 2, 2020, the Company issued two convertible promissory notes with an aggregate principal amount of $107,000, with the Company receiving proceeds of $100,000 after original issue discount of $5,000 and deferred finance costs of $2,000. The notes mature in September 2021 and bear interest at 12% per annum. Commencing one hundred eighty (180) days following the issuance date of the notes, the noteholders shall have the right to convert all or any part of the outstanding and unpaid principal balance of the note, at any time, into shares of common stock of the Company at variable conversion price of 60% of the lowest previous twenty (20) trading day closing trade prices of the Company’s common stock, subject to adjustment. The Company is prohibited from effecting a conversion of the note to the extent that, as a result of such conversion, the noteholder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the note.

Subsequent Events

Subsequent Events	3 Months Ended
	Nov. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 14 - Subsequent Events On December 1, 2020, the Company entered into a Securities Purchase Agreement in connection with the issuance of an 8% convertible note with the principal amount of $33,500, with an accredited investor. The note is convertible anytime after 180 days of issuance at a variable conversion price of 63% of the Market Price at time of conversion. Market Price is defined as the average of the two lowest trading prices during the fifteen (15) days prior to conversion. The Company received net cash proceeds of $30,000. On January 3, 2021, we entered into a settlement agreement with Robert L. Hymers, III (“Hymers”) concerning five delinquent payments totaling $100,000 due under the stock purchase agreement whereby the Company purchased 266,667 shares of common stock of Natural Plant Extract of California Inc., a California corporation (“NPE”), The Company was required to make $20,000 monthly for a period of twenty-seven (27) months to Hymers, with the first payment commencing September 1, 2020 and the remaining payments due and payable on the first day of each subsequent month until Hymers received $540,000. On January 3, 2021, we entered into a settlement concerning the outstanding payments by agreeing to issue to Hymers a total of 1,585,791 shares of registered common stock from our S-1 registration statement made effective November 12, 2020. On January 5, 2021, the Company entered into a Securities Purchase Agreement in connection with the issuance of an 10% convertible note with the principal amount of $110,000, with an accredited investor. The note is convertible at a fixed conversion price of $0.05. In the event of default by the Company, or after the public announcement of a change of control transaction as defined in the agreement, the conversion price is $0.01. The Company received net proceeds of $97,500. On January 12, 2021, the Company entered into a Securities Purchase Agreement in connection with the issuance of an 10% convertible note with the principal amount of $115,500, with an accredited investor. The note is convertible beginning 61 days from issuance at a fixed conversion price of $0.10 per share or 60% or the lowest trading price for ten days prior to conversion in the event that the Company’s stock trades at less than $0.10 per share. The Company received net proceeds of $100,000.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Nov. 30, 2020
Accounting Policies [Abstract]
Consolidation	Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Variable Interest Entities	Variable Interest Entities The Company accounts for arrangements that are not controlled through voting or similar rights as variable interest entities (“VIEs”). An enterprise is required to consolidate a VIE if it is the primary beneficiary of the VIE. A VIE is created when (i) the equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support from other parties, or (ii) the entity’s equity holders as a group either: (a) lack the power, through voting or similar rights, to direct the activities of the entity that most significantly impact the entity’s economic performance, (b) are not obligated to absorb expected losses of the entity if they occur, or (c) do not have the right to receive expected residual returns of the entity if they occur. If an entity is deemed to be a VIE, the enterprise that is deemed to have a variable interest, or combination of variable interests, that provides the enterprise with a controlling financial interest in the VIE, is considered the primary beneficiary and must consolidate the VIE. Investments where the Company has significant influence, but not control, and joint ventures which are VIEs in which the Company is not the primary beneficiary, are recorded under the equity method of accounting on the accompanying consolidated financial statements. As of November 30, 2020, the Company held a variable interest in an entity for which it directly held an 18.8% equity interest, and indirectly controlled 37.6% of the equity. The entity was not determined to be a VIE under ASC 810, as it did not meet the criteria outlined above. Since the Company indirectly controls less than 50% of the voting interest of the entity, the entity is not consolidated, and the Company accounts for the investment under the equity method of accounting in accordance with ASC 321. Since the entity in which the Company holds its investment does not have a readily determinable fair value, the Company elected to account for the investment under the measurement alternative, accounting for the investment at cost less impairment, plus or minus any changes resulting from observable price changes in orderly transactions for the same investment. See Note 8 for additional information on this investment.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of August 30, 2020 and through the date of this report. The matters assessed included accounts receivable and the carrying value of investments, intangible assets and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents are held in operating accounts at a major financial institution.
Inventory	Inventory Inventory is primarily comprised of work in progress. Inventory is valued at cost, based on the specific identification method, unless and until the net realizable value for the inventory is lower than cost, in which case an allowance is established to reduce the valuation to the net realizable value. As of August 31, 2020, and August 31, 2019, market values of all of our inventory were at cost, and accordingly, no such valuation allowance was recognized.
Deposits	Deposits Deposits is comprised of advance payments made to third parties, primarily for inventory for which we have not yet taken title. When we take title to inventory for which deposits are made, the related amount is classified as inventory, then recognized as a cost of revenues upon sale (see “Costs of Revenues” below). There were no deposits as of November 30, 2020 or August 31, 2020.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets is primarily comprised of advance payments made to third parties for independent contractors’ services or other general expenses. Prepaid services and general expenses are amortized over the applicable periods which approximate the life of the contract or service period.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at the net value of face amount less any allowance for doubtful accounts. On a periodic basis, we evaluate our accounts receivable and, based on a method of specific identification of any accounts receivable for which we deem the net realizable value to be less than the gross amount of accounts receivable recorded, we establish an allowance for doubtful accounts for those balances. In determining our need for an allowance for doubtful accounts, we consider historical experience, analysis of past due amounts, client creditworthiness and any other relevant available information. However, our actual experience may vary from our estimates. If the financial condition of our clients were to deteriorate, resulting in their inability or unwillingness to pay our fees, we may need to record additional allowances or write-offs in future periods. This risk is mitigated to the extent that we collect retainers from our clients prior to performing significant services. The allowance for doubtful accounts, if any, is recorded as a reduction in revenue to the extent the provision relates to fee adjustments and other discretionary pricing adjustments. To the extent the provision relates to a client's inability to make required payments on accounts receivables, the provision is recorded in operating expenses. As of November 30 2020, and November, 2019, we had $0 and $0 allowance for doubtful accounts, respectively.
Property and Equipment, net	Property and Equipment, net Property and Equipment is stated at net book value, cost less depreciation. Maintenance and repairs are expensed as incurred. Depreciation of owned equipment is provided using the straight-line method over the estimated useful lives of the assets, ranging from two to seven years. Depreciation of capitalized construction in progress costs, a component of property and equipment, net, begins once the underlying asset is placed into service and is recognized over the estimated useful life. Property and equipment is reviewed for impairment as discussed below under “Accounting for the Impairment of Long-Lived Assets.” We did not capitalize any interest as of November 30, 2020, and as of November 30, 2019.
Accounting for the Impairment of Long-Lived Assets	Accounting for the Impairment of Long-Lived Assets We evaluate long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Upon such an occurrence, recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to forecasted undiscounted net cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. For long-lived assets held for sale, assets are written down to fair value, less cost to sell. Fair value is determined based on discounted cash flows, appraised values or management's estimates, depending upon the nature of the assets. We have not recorded any impairment charges related to long-lived assets during the year ended November 30, 2020, and as of November 30, 2019.
Beneficial Conversion Feature	Beneficial Conversion Feature If the conversion features of conventional convertible debt provides for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature (“BCF”). We record a BCF as a debt discount pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ACF”) Topic 470-20 Debt with Conversion and Other Options. In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and we amortize the discount to interest expense over the life of the debt using the effective interest method.
Revenue Recognition	Revenue Recognition In accordance with FASB ASC Topic 606, Revenue Recognition, we recognize revenue when persuasive evidence of a significant financing component exists in our consulting and product sales contracts. We examine and evaluate when our customers become liable to pay for goods and services; how much consideration is paid as compared to the cash selling price of the goods or services; and, the length of time between our performance and the receipt of payment.
Product Sales	Product Sales Revenue from product sales, including delivery fees, is recognized at a point in time when control of the promised goods is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods. Generally, we drop-ship orders to our clients with shipping-point or destination terms. For any shipments with destination terms, the Company defers revenue until delivery to the customer. Given the facts that (1) our customers exercise discretion in determining the timing of when they place their product order; and, (2) the price negotiated in our product sales is fixed and determinable at the time the customer places the order, we are not of the opinion that our product sales indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for us or the customer under FASB ASC Topic 606.
Costs of Revenues	Costs of Revenues Our policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenues include the costs directly attributable to revenue recognition and includes compensation and fees for services, travel and other expenses for services and costs of products and equipment. Selling, general and administrative expenses are charged to expense as incurred.
Stock-Based Compensation	Stock-Based Compensation Restricted shares are awarded to employees and entitle the grantee to receive shares of restricted common stock at the end of the established vesting period. The fair value of the grant is based on the stock price on the date of grant. We recognize related compensation costs on a straight-line basis over the requisite vesting period of the award, which to date has been one year from the grant date.
Income Taxes	Income Taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns in accordance with applicable accounting guidance for accounting for income taxes, using currently enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. As of November 30, 2020, and August 31, 2020, we had no liabilities related to federal or state income taxes.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share We report net income (loss) per common share in accordance with FASB ASC 260, “Earnings per Share”. This statement requires dual presentation of basic and diluted earnings with a reconciliation of the numerator and denominator of the earnings per share computations. Basic net income (loss) per share is computed by dividing net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period and excludes the effects of any potentially dilutive securities. Diluted net income (loss) per share gives effect to any dilutive potential common stock outstanding during the period. The computation does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings.

Derivative Liability and Fair_2

Derivative Liability and Fair Value Measurements (Tables)	3 Months Ended
	Nov. 30, 2020
Notes to Financial Statements
Fair Value, Assets Measured on Recurring Basis	Items recorded or measured at fair value on a recurring basis in the accompanying financial statements consisted of the following items as of November 30, 2020 and August 31, 2020: November 30, Quoted Significant Significant Derivative liability $ 1,139,952 $ — $ — $ 1,139,952 August 31, Quoted Significant Significant Derivative liability $ 1,125,803 $ — $ — $ 1,125,803
Summary of changes in fair value of Level 3 financial liabilities	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities for the three months ended November 30, 2020: Balance, August 31, 2020 $ 1,125,803 Transfers in due to issuance of convertible promissory notes 729,826 Transfers out due to repayments of convertible promissory notes (139,431 ) Transfers out due to conversions of convertible promissory notes — Mark to market to November 30, 2020 1,716,198 Balance, November 30, 2020 $ 1,139,952 Gain on change in derivative liability for the three months ended November 30, 2020 $ (576,246 )

Organization and Description _2

Organization and Description of Business (Details Narrative) - USD ($)	Jan. 03, 2021	Jun. 15, 2020	Nov. 16, 2020	Sep. 30, 2020	Jul. 22, 2020	May 25, 2019	Nov. 30, 2020	Jan. 02, 2020	Jul. 01, 2019
Common stock, shares sold			3,000,000
Proceeds from sale of common stock			$ 177,000
Ethos Technology LLC [Member]
Shares issued for business acquisition			6,000,000
Stock Purchase Agreement
Common stock, shares issued							266,667
Chief Executive Officer [Member]
Accounts Payable									$ 1,000
Lelantos
Issuance promissory note		$ 500,000
Common stock, shares issued		400,000
Whisper [member]
Restricted common stock					$ 150,000
Shareholder | Stock Purchase Agreement
Common stock purchase price							$ 2,040,000
Debt default								$ 100,000
Hymers [Member] | Settlement Agreement [Member] | Subsequent Event [Member]
Stock issued under agreement	1,585,791
Edward Manolos [Member]
Common stock, shares sold			1,500,000
Edward Manolos [Member] | Ethos Technology LLC [Member]
Shares issued for business acquisition			1,500,000
Additional shares issued to related parties			1,500,000
Thang Nguyen [Member]
Common stock, shares sold			1,500,000
Thang Nguyen [Member] | Ethos Technology LLC [Member]
Shares issued for business acquisition			1,500,000
Additional shares issued to related parties			1,500,000
Lauderdale Holdings, LLC [Member]
Common stock, shares outstanding, percentage						70.70%
Lauderdale Holdings, LLC [Member] | Mr. Robert Hymers [Member]
Common stock, shares sold						43,333,333
Proceeds from sale of common stock						$ 108,333
Lauderdale Holdings, LLC [Member] | Edward Manolos [Member]
Common stock, shares sold						43,333,333
Proceeds from sale of common stock						$ 108,333
Lauderdale Holdings, LLC [Member] | Mr. Dan Nguyen [Member]
Common stock, shares sold						43,333,333
Proceeds from sale of common stock						$ 108,333
Lauderdale Holdings, LLC [Member] | Unaffiliated Parties [Member]
Common stock, shares sold						130,000,000
Proceeds from sale of common stock						$ 325,000
Marijuana Company of America, Inc [Member]
Shares issued for exchange of shares				7,222,222
Number of common stock exchanged				650,000,000

Going Concern Uncertainties a_2

Going Concern Uncertainties and Liquidity Requirements (Details Narrative) - USD ($)	3 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Aug. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Deficit	$ (6,410,173)		$ (6,056,949)
Revenues	$ 4,530	$ 10,003

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Nov. 30, 2020	Nov. 30, 2019	Aug. 31, 2020
Accounting Policies [Abstract]
Variable interest	18.80%
Deposits	$ 0		$ 0
Allowance for doubtful accounts	0		$ 0
Impairment charges	0	$ 0
Income taxes	$ 0	$ 0

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - Split Tee - USD ($)	Jul. 09, 2019	Sep. 30, 2020	Aug. 31, 2020	Aug. 23, 2019
Notes Receivable	$ 20,000	$ 0		$ 20,000
Interest rate	10.00%
Allowance for doubtful accounts			$ 40,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	1 Months Ended
	Nov. 16, 2020USD ($)$ / sharesshares
Common stock, shares sold	3,000,000
Proceeds from sale of common stock | $	$ 177,000
Sale of stock price per share | $ / shares	$ 0.001
Edward Manolos [Member]
Common stock, shares sold	1,500,000
Thang Nguyen [Member]
Common stock, shares sold	1,500,000
Ethos Technology LLC [Member]
Shares issued for business acquisition	6,000,000
Ethos Technology LLC [Member] | Edward Manolos [Member]
Shares issued for business acquisition	1,500,000
Additional shares issued to related parties	1,500,000
Ethos Technology LLC [Member] | Thang Nguyen [Member]
Shares issued for business acquisition	1,500,000
Additional shares issued to related parties	1,500,000

Note Payable (Details Narrative

Note Payable (Details Narrative) - USD ($)	Feb. 12, 2020	Jul. 09, 2019	Sep. 24, 2020	Sep. 22, 2020	Feb. 20, 2020	May 25, 2019	Nov. 30, 2020	Aug. 31, 2020	Aug. 23, 2019
Interest rate			10.00%	8.00%
Principal amount			$ 78,000	$ 78,000
Maturity date			Jun. 24, 2021	Sep. 22, 2021
Accrued interest payable							$ 95,967	$ 33,301
Split Tee
Note payable		$ 20,000							$ 20,000
Interest rate		10.00%
Consulting fee		$ 5,000
Lelantos
Business acquisition, shares issued					400,000
Issuance promissory note					$ 500,000
Edward Manolos
Note payable						$ 1,666,667
Interest rate						5.00%
Compensation Promissory Note | Consulting Agreement | Consultant
Interest rate	8.00%
Principal amount	$ 100,000
Maturity date	Aug. 4, 2020
Carrying value							100,000	100,000
Accrued interest payable							$ 6,400	$ 4,405

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)	Jan. 03, 2021	Sep. 02, 2020	Jan. 31, 2021	Dec. 31, 2020	Oct. 31, 2020	Sep. 24, 2020	Sep. 22, 2020	Aug. 31, 2020	Aug. 21, 2020	Jul. 21, 2020	May 22, 2020	Apr. 30, 2020	Mar. 19, 2020	Nov. 30, 2020	Feb. 29, 2020	Nov. 30, 2019
Principal amount						$ 78,000	$ 78,000
Proceeds from Convertible debt														$ 427,500		$ 20,000
Interest rate						10.00%	8.00%
Accrued interest payable								$ 33,301						95,967
Maturity date						Jun. 24, 2021	Sep. 22, 2021
Conversion price						$ 0.06
Repayment of convertible debt														75,000		$ 0
Chief Executive Officer [Member]
Principal amount															$ 79,333
Robert L. Hymers III [Member]
Principal amount															53,768
Chief Financial Officer [Member]
Interest rate												10.00%
Interest expense												$ 30,000
Carrying value								15,884						22,670
Debt discount								37,884						31,098
Accrued interest payable								3,138						4,479
Maturity date												Dec. 31, 2020
Beneficial Conversion Feature												$ 30,000
Chief Financial Officer [Member] | Principal
Conversion of Stock, Shares Converted					1,500,000
Former Chief Financial Officer [Member]
Accrued interest payable														1,759
Conversion price												$ 0.02
NPE
Initial investment														1,714,903
Investment income														148,015
Common stock subscription agreements | Lender
Proceeds from Convertible debt								$ 329,613
Interest rate								10.00%
Interest expense								$ 50,000
Carrying value								3,288						15,754
Debt discount								46,712						34,246
Accrued interest payable								$ 329						1,580
Convertible debt														$ 50,000
Beneficial ownership percentage														4.99%
Conversion of Stock, Shares Converted								3,409,221
Maturity date								Aug. 7, 2021
StockPurchaseAgreement | NPE
Interest rate									10.00%
Debt discount									$ 270,886
Beneficial ownership percentage									4.99%
Initial investment									$ 1,714,903
Stock Issued During Period, Shares, Acquisitions									266,667
Debt default									$ 100,000
Subsequent Event [Member] | Chief Financial Officer [Member] | Principal and Accrued Interest [Member]
Conversion of Stock, Shares Converted				878,190
Subsequent Event [Member] | Hymers [Member]
Shares issued for settlement of debt	1,585,791
Convertible Promissory Note
Principal amount													$ 150,000
Original issue discount													$ 15,000
Warrants exercisable													468,750
Interest rate													10.00%
Interest expense													$ 75,000
Carrying value								$ 37,088						$ 14,187
Debt discount								62,912						10,813
Accrued interest payable								3,431						979
Warrant grant term													3 years
Warrant granted price													$ 0.48
Beneficial ownership percentage													4.99%
Repayment of convertible debt														75,000
Repayment of accrued interest														3,712
Repayment interest and penalties														40,913
Convertible Promissory Note | Subsequent Event [Member]
Repayment of convertible debt			$ 39,875
Convertible Promissory Note
Principal amount										$ 78,750
Original issue discount										3,750
Deferred finance costs										3,750
Proceeds from Convertible debt										$ 71,250
Interest rate										6.00%
Interest expense										$ 78,750
Carrying value								8,846						28,480
Debt discount								69,904						50,270
Accrued interest payable								531						1,709
Beneficial ownership percentage										4.99%
Maturity date										Jul. 21, 2021
Two Convertible Promissory Notes
Principal amount								129,250
Original issue discount								11,750
Proceeds from Convertible debt								$ 117,500
Interest rate								10.00%
Interest expense								$ 129,250
Carrying value								8,452						51,535
Debt discount								120,798						77,715
Accrued interest payable								$ 632						3,862
Beneficial ownership percentage								4.99%
Maturity date								May 31, 2021
Three Convertible Promissory Notes
Principal amount														246,000
Deferred finance costs														9,000
Proceeds from Convertible debt														$ 237,000
Interest rate														8.00%
Interest expense														$ 246,000
Carrying value														53,315
Debt discount														192,685
Accrued interest payable														$ 3,882
Beneficial ownership percentage														4.99%
Convertible Promissory Note
Principal amount		$ 107,000
Original issue discount		5,000
Deferred finance costs		2,000
Proceeds from Convertible debt		100,000
Interest expense		$ 107,000
Carrying value														$ 26,090
Debt discount														80,910
Accrued interest payable														3,131
Beneficial ownership percentage		4.99%
Maturity date		Sep. 30, 2021
Convertible Promissory Note
Principal amount						$ 110,000
Proceeds from Convertible debt						$ 90,500
Interest rate						10.00%
Carrying value														95,214
Debt discount														14,786
Accrued interest payable														$ 1,989
Beneficial ownership percentage						4.99%
Maturity date						Jun. 24, 2021
Conversion price						$ 0.06
Periodic payment						$ 24,200
Frequency of periodic payment						Monthly
Two Convertible Promissory Notes
Principal amount															$ 133,101
Interest rate															10.00%
Interest expense															$ 133,101
Two Convertible Promissory Notes | Tabatabaei
Conversion of Stock, Amount Converted											$ 232,792
Conversion of Stock, Shares Converted											694,902
Gain on conversion											$ 10,468
Two Convertible Promissory Notes | Tabatabaei | Principal
Conversion of Stock, Amount Converted											79,333
Two Convertible Promissory Notes | Tabatabaei | Interest
Conversion of Stock, Amount Converted											$ 2,608

Derivative Liability and Fair_3

Derivative Liability and Fair Value Measurements (Details) - USD ($)	Nov. 30, 2020	Aug. 31, 2020
Derivative liability	$ 1,139,952	$ 1,125,803
Fair Value, Inputs, Level 1 [Member]
Derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative liability	$ 1,139,952	$ 1,125,803

Derivative Liability and Fair_4

Derivative Liability and Fair Value Measurements (Details 1)	3 Months Ended
	Nov. 30, 2020USD ($)
Notes to Financial Statements
Balance at beginning	$ 1,125,803
Transfers in due to issuance of convertible promissory notes	729,826
Transfers out due to repayments of convertible promissory notes	(139,431)
Transfers out due to conversions of convertible promissory notes	0
Mark to market	1,716,198
Balance at end	1,139,952
Gain on change in derivative liability	$ (576,246)

Derivative Liability and Fair_5

Derivative Liability and Fair Value Measurements (Details Narrative)	3 Months Ended
	Nov. 30, 2020USD ($)
Fair value of embedded derivatives	$ 1,139,952
Dividend yield	0.00%
Expected volatility	374.00%
Minimum [Member]
Risk-free interest rate	0.09%
Expected life (in years)	3 months 19 days
Maximum [Member]
Risk-free interest rate	0.11%
Expected life (in years)	1 year 1 month 6 days
Convertible Notes Payable [Member]
Fair value of embedded derivatives	$ 729,827
Dividend yield	0.00%
Expected life (in years)	1 year
Convertible Notes Payable [Member] | Minimum [Member]
Expected volatility	373.00%
Risk-free interest rate	0.12%
Convertible Notes Payable [Member] | Maximum [Member]
Expected volatility	378.00%
Risk-free interest rate	0.13%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	3 Months Ended
	Nov. 30, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
Finance lease	$ 0
Lease expiration date	Aug. 14, 2020

Common Stock (Details Narrative

Common Stock (Details Narrative) - shares	3 Months Ended
	Nov. 30, 2020	Aug. 31, 2020
Equity [Abstract]
Reverse stock split, description	At the rate of one (1) share for each fifteen (15) shares.
Common stock, shares issued	39,714,845	27,082,419
Common stock, shares outstanding	39,714,845	27,082,419

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - $ / shares	1 Months Ended
	May 28, 2020	Dec. 16, 2019	Nov. 30, 2020	Aug. 31, 2020
Preferred stock, shares authorized			10,000,000	10,000,000
Preferred stock, par or stated value per share			$ 0.0001	$ 0.0001
Preferred stock, shares issued			6,000,000	6,000,000
Preferred stock, shares outstanding			6,000,000	6,000,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized		8,000,000
Preferred stock, voting right		Holders of Series A Preferred Stock shall be entitled to 50 votes for every Share of Series A Preferred Stock
Shares returned during the period	2,000,000
Preferred stock, shares issued			6,000,000
Preferred stock, shares outstanding			6,000,000

Other Reportable Events (Detail

Other Reportable Events (Details Narrative) - USD ($)	Sep. 02, 2020	Nov. 16, 2020	Oct. 30, 2020	Sep. 30, 2020	Sep. 24, 2020	Sep. 22, 2020	May 25, 2019	Nov. 30, 2020	Nov. 30, 2019
Common stock, shares sold		3,000,000
Proceeds from sale of common stock		$ 177,000
Sale of stock price per share		$ 0.001
Principal amount					$ 78,000	$ 78,000
Interest rate					10.00%	8.00%
Maturity date					Jun. 24, 2021	Sep. 22, 2021
Conversion price					$ 0.06
Proceeds from Convertible debt								$ 427,500	$ 20,000
Convertible Promissory Note
Principal amount	$ 107,000
Maturity date	Sep. 30, 2021
Original issue discount	$ 5,000
Deferred finance costs	2,000
Proceeds from Convertible debt	$ 100,000
Beneficial ownership percentage	4.99%
Marijuana Company of America, Inc [Member]
Shares issued for exchange of shares				7,222,222
Number of common stock exchanged				650,000,000
Jim Riley [Member]
Shares issued for compensation			400,000
Edward Manolos [Member]
Common stock, shares sold		1,500,000
Interest rate							5.00%
Thang Nguyen [Member]
Common stock, shares sold		1,500,000
Ethos Technology LLC [Member]
Shares issued for business acquisition		6,000,000
Ethos Technology LLC [Member] | Edward Manolos [Member]
Shares issued for business acquisition		1,500,000
Additional shares issued to related parties		1,500,000
Ethos Technology LLC [Member] | Thang Nguyen [Member]
Shares issued for business acquisition		1,500,000
Additional shares issued to related parties		1,500,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jan. 12, 2021	Jan. 05, 2021	Jan. 03, 2021	Dec. 02, 2020	Sep. 24, 2020	Sep. 22, 2020	Nov. 30, 2020	Nov. 30, 2019
Principal amount					$ 78,000	$ 78,000
Proceeds from Convertible debt							$ 427,500	$ 20,000
Interest rate					10.00%	8.00%
Conversion price					$ 0.06
Subsequent Event [Member] | Hymers [Member]
Shares issued for settlement of debt			1,585,791
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Principal amount				$ 33,500
Proceeds from Convertible debt				$ 30,000
Interest rate				8.00%
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Principal amount	$ 115,500	$ 110,000
Proceeds from Convertible debt	$ 100,000	$ 97,500
Interest rate	10.00%	10.00%
Conversion price	$ 0.10	$ 0.05